EPS holds flat sequentially. Biote Corp reported adjusted earnings per share of $0.06 for Q4 2025, but down 83.8% from the year-ago quarter’s $0.37. The medical care facilities provider posted net income of $2.6 million on adjusted EBITDA of $11.7 million. Operating income came in at $6.8 million as gross profit of $31.5 million offset cost of revenue of $14.9 million.
Revenue essentially flat year-over-year. The company generated revenue of $46.4 million, down 0.6% from $49.8 million in Q4 2024. Sequential revenue held steady at $49.5 million versus Q3’s $48.0 million. Management issued full-year 2026 revenue guidance of at least $190 million, implying quarterly run-rate acceleration from current levels. The stock traded at $1.79 on volume of 277,529 shares, near its 52-week low of $1.68.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.